Capsugel launches enTRinsic drug delivery technology platform
Offers full enteric protection without the need for functional coatings
US dosage forms specialist Capsugel has launched its enTRinsic drug delivery technology platform, which offers full enteric protection without the need for functional coatings and enables targeted release of gastric acid- and heat-sensitive active ingredients to the upper gastrointestinal tract.
Capsugel says enTRinsic enables oral delivery of a variety of compounds – including vaccines, proteins and peptides – using pharmaceutically approved enteric polymers.
'Capsugel’s enTRinsic drug delivery technology is the result of our continued commitment to innovate for our customers,' said Amit Patel, President, Capsugel Dosage Form Solutions.
'For years the industry has been searching for a fully enteric dosage form that doesn’t require functional coatings. By leveraging Capsugel’s unique combination of formulation, polymer chemistry and manufacturing expertise, we have developed a novel solution for enteric protection and the targeted delivery of a wide range of sensitive molecules.'
Our lead-user programme confirmed the enteric performance of our enTRinsic technology in multiple applications
The technology is now globally available for customer projects following the completion of an 18-month lead-user customer-collaboration programme that included feasibility studies with new and existing pharmaceutical products.
'Our lead-user programme confirmed the enteric performance of our enTRinsic technology in multiple applications, as well as the viability of the formulation and manufacture of finished drug product at scale,' said Keith Hutchison, Senior Vice President, Research and Development, Capsugel.
'We are now excited to move beyond the lead-user programme and work with additional customers, while continuing to broaden the application of the technology to encompass gastric resistance, full enteric protection, and varied GI site targeting for an increasingly diverse range of APIs.'
Capsugel's enTRinsic technology further expands the company’s range of modified and targeted release solutions, as well as its biotherapeutic formulation offering.
Customers can access the technology platform through a services agreement at Capsugel’s locations in Ploërmel, France, and Bend, Oregon, US. It can be tailored to specific customer projects and combined with other technologies to meet various target product profiles and commercial objectives.
